InvestorsHub Logo
Followers 35
Posts 4291
Boards Moderated 0
Alias Born 12/12/2007

Re: None

Sunday, 08/02/2020 9:16:33 AM

Sunday, August 02, 2020 9:16:33 AM

Post# of 409457
Just a footnote for fresh eyes.


NORTHVALE, NJ / ACCESSWIRE / June 29, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2020 ("Fiscal 2020").

Consolidated revenues for Fiscal 2020 were $18.0 million, an increase of $10.4 million or approximately 137% from the comparable period of the prior fiscal year. The increase in revenues was largely attributed to revenues from products launched during the 2020 Fiscal Year, generic immediate release Adderall®, generic extended release Adderall®, and generic Dantrolene Capsules, as well as strong growth in revenues relating to the sales of Isradipine capsules.


https://finance.yahoo.com/news/elite-pharmaceuticals-inc-reports-financial-225500663.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News